Scarica l'app Stockscreener
1.655
1.22%
0.015
Precedente Chiudi:
$1.64
Aprire:
$1.62
Volume 24 ore:
119.38K
Relative Volume:
0.16
Capitalizzazione di mercato:
$87.70M
Reddito:
$139.77M
Utile/perdita netta:
$-97.62M
Rapporto P/E:
-1.0475
EPS:
-1.58
Flusso di cassa netto:
$-61.71M
1 W Prestazione:
+9.21%
1M Prestazione:
+31.75%
6M Prestazione:
-50.30%
1 anno Prestazione:
-88.80%
Intervallo 1D:
$1.58
$1.66
Intervallo di 1 settimana:
$1.57
$1.81
Portata 52W:
$0.9897
$16.44
Macrogenics Inc Stock (MGNX) Company Profile
Nome
Macrogenics Inc
Settore
Industria
Telefono
301-251-5172
Indirizzo
9704 MEDICAL CENTER DRIVE, Rockville, MD
Confronta MGNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.655 | 87.70M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.80 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.47 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.64 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
258.54 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.31 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-07 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-01 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-31 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2024-07-31 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-05-10 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-05-10 | Downgrade | Stifel | Buy → Hold |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2024-04-26 | Iniziato | B. Riley Securities | Buy |
| 2024-04-09 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-03-04 | Reiterato | BTIG Research | Buy |
| 2024-02-14 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-12-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-17 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-11-22 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-11-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2022-07-18 | Downgrade | SMBC Nikko | Outperform → Neutral |
| 2022-07-11 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-05-04 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-02-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-02-11 | Iniziato | BMO Capital Markets | Outperform |
| 2022-02-04 | Iniziato | SMBC Nikko | Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Buy |
| 2021-10-19 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-10-15 | Ripresa | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-12 | Aggiornamento | Barclays | Underweight → Overweight |
| 2020-12-22 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-03 | Downgrade | Citigroup | Buy → Neutral |
| 2020-06-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-04 | Iniziato | Barclays | Underweight |
| 2019-12-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-11-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-11-20 | Ripresa | Guggenheim | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Guggenheim | Neutral |
| 2019-02-07 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-02-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-02-06 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2019-02-04 | Downgrade | Citigroup | Neutral → Sell |
| 2018-12-10 | Downgrade | Raymond James | Outperform → Underperform |
| 2018-09-10 | Ripresa | BTIG Research | Buy |
| 2018-05-31 | Iniziato | Evercore ISI | Outperform |
| 2018-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-31 | Iniziato | Raymond James | Outperform |
Mostra tutto
Macrogenics Inc Borsa (MGNX) Ultime notizie
Press Release Distribution & PR Platform - ACCESS Newswire
MGNXMacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
The MGNX Stock Puzzle: Unraveling Macrogenics Inc’s Fluctuating Performance - investchronicle.com
MacroGenics Provides Update on Corporate Progress and 1st Quarter 2017 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results - ADVFN
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
MacroGenics Provides Update on Corporate Progress and First Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2021 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Third Quarter 2015 Financial Results - ADVFN
Investor Expectations to Drive Momentum within LPL Financial, Comcast, MacroGenics, Wayfair, Masimo, and Big Lots — Discove... - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2019 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results - ADVFN
MacroGenics Provides Update on Corporate Progress and Second Quarter 2021 Financial Results - ADVFN
Comparing Ensysce Biosciences (NASDAQ:ENSC) & MacroGenics (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.38 Average Price Target from Analysts - Defense World
MacroGenics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsMGNX - marketscreener.com
American Century Companies Inc. Buys Shares of 11,743 MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Looks Inexpensive After Falling 42% But Perhaps Not Attractive Enough - simplywall.st
Wellington Management Group LLP Acquires 16,717 Shares of MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
ATTENTION MGNX SHAREHOLDERS: Investors who lost money on MacroGenics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation - ACCESS Newswire
Next Generation Immunotherapies Market Growth Projections - openPR.com
MGNX Deadline in 5 Days: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - marketscreener.com
Class Action Filed Against MacroGenics, Inc. (MGNX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on MacroGenics, Inc.(MGNX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
908 Devices Leads These 3 Penny Stocks To Consider - simplywall.st
MGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that MacroGenics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATTENTION MacroGenics, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of MacroGenics, Inc. (MGNX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor SuitHagens Berman - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 24, 2024 in MacroGenics, Inc. LawsuitMGNX - ACCESS Newswire
MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Levi & Korsinsky Reminds MacroGenics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 24, 2024MGNX - ACCESS Newswire
MacroGenics, Inc. (NASDAQ:MGNX) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Has $540,000 Stock Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Macrogenics Inc Azioni (MGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Macrogenics Inc Azioni (MGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Karrels James | SVP, CFO and Secretary |
Feb 15 '25 |
Option Exercise |
0.00 |
14,998 |
0 |
192,591 |
| Koenig Scott | President and CEO |
Feb 15 '25 |
Option Exercise |
0.00 |
42,329 |
0 |
777,415 |
| Peters Jeffrey Stuart | Senior VP and General Counsel |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
18,858 |
| Risser Eric Blasius | Chief Operating Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
62,422 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Option Exercise |
0.00 |
1,095 |
0 |
9,955 |
| Smith Beth Ann | VP, Controller & Treasurer |
Feb 15 '25 |
Sale |
2.56 |
423 |
1,083 |
9,532 |
| Spitznagel Thomas | Sr VP, Technical Ops |
Feb 15 '25 |
Option Exercise |
0.00 |
13,332 |
0 |
26,922 |
| Eck Stephen L. | Chief Medical Officer |
Feb 15 '25 |
Option Exercise |
0.00 |
16,665 |
0 |
34,319 |
| Eck Stephen L. | Chief Medical Officer |
Feb 08 '25 |
Option Exercise |
0.00 |
11,168 |
0 |
20,966 |
| SIEGEL JAY PHILIP | Director |
May 20 '24 |
Option Exercise |
0.00 |
4,500 |
0 |
4,500 |
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):